Ambrx Taking ADCs Beyond Cancer in $303M Merck Deal
BOSTON – Ambrx Inc. helped kick off the BIO International Convention Monday by disclosing a potential $303 million collaboration with Merck & Co. Inc. using its EuCODE platform to develop antibody-drug conjugates (ADCs) against oncology and other indications.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST